摘要
[目的]探讨莫西沙星和左氧氟沙星治疗慢性阻塞性肺疾病急性加重期成本效果。[方法]选择我院收治的慢性阻塞性肺疾病急性加重期患者90例,随机分为莫西沙星组和左氧氟沙星组(每组45例)。两组给予吸氧、祛痰止喘等治疗,莫西沙星组和左氧氟沙星组分别给予莫西沙星和左氧氟沙星治疗。评定两组治疗效果和成本效果。[结果]莫西沙星组总有效率高于左氧氟沙星组,差异有统计学意义(P<0.05)。莫西沙星组成本/效果低于左氧氟沙星组成本/效果。[结论]莫西沙星治疗慢性阻塞性肺疾病急性加重期的成本效果低于左氧氟沙星,值得借鉴。
[Obje ct ive]To evaluate the cost-effectiveness of moxifloxacin and levofloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease （ COPD）. [ Metliod-S ] 90 patients with acute exacerbation of chronic obstructive pulmonary disease in our hospital were randomly divided into moxifloxacin group and levofloxacin group （ n = 45） . The two groups were treated with oxygen inhalation, expectorant and antiasthmatic treatment, and moxifloxacin group and levofloxacin group were treated with moxifloxacin and levofloxacin respectively. The treatment effect and cost effect of two groups were evaluated. [Results]The total effective rate of moxifloxacin group was higher than that of levofloxacin group, the difference was statistically significant （ P 〈 0.05） . The cost / effectiveness of moxifloxacin group was lower than that of levofloxacin group. [Conclusion]The Cost effectiveness of moxifloxacin is lower than that of levofloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease, which is worth of reference.
出处
《河南大学学报（医学版）》
CAS
2017年第3期179-181,共3页
Journal of Henan University:Medical Science
关键词
慢性阻塞性肺疾病
急性加重期
莫西沙星
左氧氟沙星
成本效果
chronic obstructive pulmonary disease
acute exacerbation
moxifloxacin
Levofloxacin
cost effectiveness
